Answers are grounded in this paper and cite their sources.
PD-1/PD-L1 blockade is not very effective in colorectal cancer and low-toxicity combination adjuvants are required. In this study, the anti-PD-1 stimulating effect of ginger-derived 6-gingerol was evaluated using MC38 cells, T cell co-cultures, PD-L1 modified cell lines and C57BL/6 mouse models and discovered that 6-gingerol suppressed surface PD-L1 expression on MC38 cells including IFN-γ-induced expression. It also augmented the effector activity of CD8+ T cells, which is typified by the upregulation of CD25, CD69 and GZMB. It is noteworthy that sub-cytotoxic doses of 6-gingerol combined with αPD-1 could stimulate the number of GZMB+ and TNFα+ T cells and suppress PD-1 expression. This sensitizing effect was absent in PD-L1-overexpressing or PD-L1-knockout MC38 cells, suggesting that it requires tumor PD-L1 in vitro. The combination treatment reduced tumor volume on day 15 (480 mm3) to 50 mm3 and enhanced intratumoral GZMB+ CD8+ T cells 7.2% to 90.3% in vivo. These results suggest that 6-gingerol can enhance antitumor immunity both directly on tumor cells and/or T cells. It can be employed as a possible adjuvant in immunotherapy of colorectal cancer.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: